Overview of Anaida
What is Anaida? Defining the Fixed-Dose Combination
| Property | Description |
|---|---|
| Active ingredient | Diclofenac and Acetaminophen (Paracetamol) |
| Form | Oral Formulation (Solid Dosage Form, typically Tablet) |
| Pharmacological Class | Non-Steroidal Anti-Inflammatory Drug (NSAID) and Non-opioid Analgesic/Antipyretic Combination |
| Common Purpose | Multimodal pain relief, inflammation, and fever reduction |
| Origin | Synthetic Chemical Entities |
Anaida is a pharmaceutical entity defined as a rational fixed-dose combination (FDC) drug intended for systemic use, typically prepared as an oral formulation. This product integrates two distinct synthetic chemical entities into a single solid dosage form, most commonly a tablet. This structural choice defines it as a distinct product type, recognized in pharmaceutical registration as a highly effective approach to managing conditions requiring dual-action agents.
Composition and Pharmacological Class of Anaida
The formulation of Anaida relies on the co-formulation of two principal active ingredients: Diclofenac and Acetaminophen (Paracetamol). This unique partnership places Anaida across two fundamental pharmacological classes. Diclofenac functions as a Non-Steroidal Anti-Inflammatory Drug (NSAID), a phenylacetic acid derivative primarily known for its anti-inflammatory action. Concurrently, Acetaminophen is categorized as a Non-opioid Analgesic/Antipyretic, providing central pain relief and fever reduction. The combination is a popular combined therapy structure often featuring in the pain management portfolios of various manufacturers, such as one prominent version available under the brand name Diclopar in some regions.
Multimodal Approach to Symptomatic Treatment
The primary purpose of the Anaida combination is to provide multimodal pain relief by simultaneously addressing inflammatory processes and central pain perception. This dual structural design is engineered to produce a powerful synergistic effect, which is recognized as a strategy for managing symptomatic relief. This combined therapy is employed for the symptomatic treatment of acute discomfort. For instance, it is utilized when an individual requires simultaneous inflammation relief and the strong pain management and fever reduction associated with musculoskeletal strains. The use of this rational drug combination is established for the purpose of addressing these combined clinical needs.
Regulatory References
